Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 1525 participants.
Also called NCT03621501
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,525 participants
- Registry
-
NCT03621501
-
- Other papers using this trial's data
- Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial
- Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome: 2-Year Results of the BIOVASC Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Unknown status
Technical summary
Registry record NCT03621501. Randomized; single masking; primary purpose treatment. Start 2018-06-22 (actual); primary completion 2022-10-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease
- Acronym
- BioVasc
- Condition
- Acute Coronary Syndrome
- Intervention (Device)
- Percutaneous coronary intervention
- Lead sponsor
- Erasmus Medical Center
- Collaborator
- Biotronik SE & Co. KG
Record details
- Record id
cardio:ct-nct03621501- Content hash
021777108ce451446f19f11f95c37870449baaefd042bbef9e2e7cea33ffb3fb